Eribulin in cancer treatment

Umang Swami; Umang Shah; Sanjay Goel

doi:10.3390/md13085016

Eribulin in cancer treatment

Umang Swami, Umang Shah, Sanjay Goel

Medicine

Research output: Contribution to journal › Review article › peer-review

52 Scopus citations

Abstract

Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic breast cancer patients who have previously been treated with an anthracycline and a taxane. It has a unique microtubule dynamics inhibitory action. Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cell lung cancer. Phase I and II studies in multiple cancers and various combinations are currently ongoing. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies, and with special focus on clinical trials.

Original language	English (US)
Pages (from-to)	5016-5058
Number of pages	43
Journal	Marine Drugs
Volume	13
Issue number	8
DOIs	https://doi.org/10.3390/md13085016
State	Published - Aug 1 2015

Keywords

Breast cancer
E7389
EMBRACE
Eribulin
Halaven
Halichondrin B
Microtubule inhibitor
NSC 707389

ASJC Scopus subject areas

Drug Discovery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/md13085016

Cite this

@article{34e506cf873d40ff853fc85f26f5d6ad,

title = "Eribulin in cancer treatment",

abstract = "Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic breast cancer patients who have previously been treated with an anthracycline and a taxane. It has a unique microtubule dynamics inhibitory action. Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cell lung cancer. Phase I and II studies in multiple cancers and various combinations are currently ongoing. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies, and with special focus on clinical trials.",

keywords = "Breast cancer, E7389, EMBRACE, Eribulin, Halaven, Halichondrin B, Microtubule inhibitor, NSC 707389",

author = "Umang Swami and Umang Shah and Sanjay Goel",

year = "2015",

month = aug,

day = "1",

doi = "10.3390/md13085016",

language = "English (US)",

volume = "13",

pages = "5016--5058",

journal = "Marine Drugs",

issn = "1660-3397",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "8",

}

TY - JOUR

T1 - Eribulin in cancer treatment

AU - Swami, Umang

AU - Shah, Umang

AU - Goel, Sanjay

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic breast cancer patients who have previously been treated with an anthracycline and a taxane. It has a unique microtubule dynamics inhibitory action. Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cell lung cancer. Phase I and II studies in multiple cancers and various combinations are currently ongoing. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies, and with special focus on clinical trials.

AB - Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic breast cancer patients who have previously been treated with an anthracycline and a taxane. It has a unique microtubule dynamics inhibitory action. Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cell lung cancer. Phase I and II studies in multiple cancers and various combinations are currently ongoing. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies, and with special focus on clinical trials.

KW - Breast cancer

KW - E7389

KW - EMBRACE

KW - Eribulin

KW - Halaven

KW - Halichondrin B

KW - Microtubule inhibitor

KW - NSC 707389

UR - http://www.scopus.com/inward/record.url?scp=84940434435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940434435&partnerID=8YFLogxK

U2 - 10.3390/md13085016

DO - 10.3390/md13085016

M3 - Review article

C2 - 26262627

AN - SCOPUS:84940434435

SN - 1660-3397

VL - 13

SP - 5016

EP - 5058

JO - Marine Drugs

JF - Marine Drugs

IS - 8

ER -

Eribulin in cancer treatment

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this